| PRECLINICAL | evidence | Swiss obesity clinical practice guidance. | Semaglutide | Weight & fat loss | 2026-05-19 |
| PRECLINICAL | evidence | Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP-1 Receptor Agonists. | Semaglutide | Addiction & substance use | 2026-05-18 |
| PRECLINICAL | evidence | Semaglutide Induces Oxidative Stress and Differentially Modulates mTOR-Dependent Growth and Invasion in Human Trophoblast Cell Models: Implications for Placental Function. | Semaglutide | — | 2026-05-18 |
| PRECLINICAL | evidence | Structure-Property-Performance Engineering of Hydrogel Depots for Long-Acting Peptide Delivery. | Semaglutide | — | 2026-05-18 |
| PRECLINICAL | evidence | Synthesis of scarless circular RNAs expressing long-acting GLP-1RAs for type 2 diabetes therapy. | Semaglutide | — | 2026-05-17 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient. | Semaglutide | — | 2026-05-16 |
| PRECLINICAL | evidence | Measuring Facial Appearance in GLP-1 Agonist Use with the FACE-Q Aesthetics Item Library. | Ozempic | — | 2026-05-15 |
| PRECLINICAL | evidence | Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort. | Semaglutide | — | 2026-05-15 |
| PRECLINICAL | evidence | Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-05-15 |
| PRECLINICAL | evidence | Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports. | Semaglutide | Glycemic control | 2026-05-15 |
| PRECLINICAL | evidence | Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management. | Semaglutide | — | 2026-05-15 |
| PRECLINICAL | evidence | CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. | Semaglutide | Weight & fat loss | 2026-05-15 |
| PRECLINICAL | evidence | Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use. | Semaglutide | — | 2026-05-14 |
| PRECLINICAL | evidence | Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications. | Semaglutide | — | 2026-05-14 |
| PRECLINICAL | evidence | Interpretable Two-Stage Machine Learning for Early and Full Drug Release Prediction in PLGA Microspheres. | Semaglutide | — | 2026-05-14 |
| PRECLINICAL | evidence | Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. | Semaglutide | — | 2026-05-14 |
| PRECLINICAL | evidence | Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review. | Semaglutide | — | 2026-05-13 |
| PRECLINICAL | evidence | GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications. | Semaglutide | — | 2026-05-13 |
| PRECLINICAL | evidence | What obgyns need to know about GLP-1 receptor agonists. | Semaglutide | — | 2026-05-12 |
| PRECLINICAL | evidence | Subcutaneous injection of semaglutide causes increased muscle uptake of (18)F-FDG and reduces the imaging quality of PET/CT: a case report. | Semaglutide | — | 2026-05-12 |
| PRECLINICAL | evidence | Endoluminal device induces insulin sensitivity and greater weight control than semaglutide in pigs. | Semaglutide | — | 2026-05-12 |
| PRECLINICAL | evidence | Angioedema After Accidental Semaglutide Dosing Error: A Case Report. | Semaglutide | — | 2026-05-12 |
| PRECLINICAL | evidence | Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. | Ozempic | Weight & fat loss | 2026-05-12 |
| PRECLINICAL | evidence | In brief: Wegovy HD - high-dose injectable semaglutide for weight loss. | Wegovy | — | 2026-05-11 |
| PRECLINICAL | evidence | Role of the GAPDH-mediated glycolysis-senescence axis in osteoarthritis chondrocytes and its modulation by semaglutide. | Semaglutide | — | 2026-05-08 |
| PRECLINICAL | evidence | Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy? | Semaglutide | Lipid & cardiovascular markers | 2026-05-07 |
| PRECLINICAL | evidence | | Semaglutide | — | 2026-05-07 |
| PRECLINICAL | evidence | Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts. | Ozempic | Weight & fat loss | 2026-05-07 |
| PRECLINICAL | evidence | The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations. | Semaglutide | — | 2026-05-07 |
| PRECLINICAL | evidence | Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. | Semaglutide | — | 2026-05-07 |
| PRECLINICAL | evidence | Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide. | Semaglutide | — | 2026-05-06 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction. | Semaglutide | — | 2026-05-05 |
| PRECLINICAL | evidence | Semaglutide improves markers of cardiovascular risk in people with HIV. | Semaglutide | — | 2026-05-05 |
| PRECLINICAL | evidence | Quality and Reliability of Semaglutide-Related Short Videos on TikTok and Bilibili. | Semaglutide | — | 2026-05-04 |
| PRECLINICAL | evidence | Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery? | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Real-world Physical Activity and Sedentary Time Trends in Patients Undergoing Obesity Treatment: Insights From the All of Us Research Program. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Tirzepatide and semaglutide: different twins? | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies. | Semaglutide | Liver health | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide for Aboriginal and Torres Strait Islander cardiovascular care: equity, cost and real-world hurdles. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Emerging natural products against obesity and metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Direct target discovery and mechanistic insights. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Genetic predictors of GLP1 receptor agonist weight loss and side effects. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Semaglutide | Mood & anxiety | 2026-05-01 |
| PRECLINICAL | evidence | Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weight Gain After Primary Bariatric Surgery? | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico. | Semaglutide | Glycemic control | 2026-05-01 |